

May 30, 2018



Navidea Biopharmaceuticals to Present at 8th Annual LD Micro Invitational Conference and Participate in the 2018 BIO International Convention

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the 8th Annual LD Micro Invitational Conference in Bel-Air, CA being held June 4-6, 2018. Jed Latkin, Chief Financial and Operating Officer of Navidea, will be giving a corporate presentation focused on Navidea's clinical programs. In addition, Michael Goldberg, M.D., Chief Executive Officer of Navidea, along with other members of management will attend the 2018 BIO International Convention in Boston, MA being held June 4-7, 2018 to participate in meetings with potential clinical and commercial partners, investors, and other parties.

Event: 8th Annual LD Micro Invitational
Presentation Date: Monday, June 4, 2018
Presentation Time: 1:00pm PT
Location: Luxe Sunset, Bel-Air, CA

The presentation at the LD Micro Invitational Conference will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the Investors presentations tab of the Investors section of the Navidea website at www.navidea.com.

The LD Micro Invitational Conference is one of the nation's largest independent conferences for small/micro-cap companies, with more than 230 names presenting to 1,000+ attendees. The conference will also feature a variety of speakers and panelists discussing topics of interest to investors and issuers, as well as evening social events.

The BIO International Convention (BIO) attracts 16,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. The Convention brings together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

To schedule a meeting with Navidea management at either conference, please contact Navidea Investor Relations at tpatel@edisongroup.com.

About BIO:

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOTechNOW is BIO's blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization's bi-weekly email newsletter.

About LD Micro:

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The firm hosts several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts.

For more information, please visit www.navidea.com.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20180530006356/en/>

Navidea Biopharmaceuticals, Inc.

Jed Latkin, 614-551-3416

CFO/COO

jlatkin@navidea.com

or

Edison Advisors

Tirth Patel, 646-653-7035

Vice President, Investor Relations

tpatel@edisongroup.com

Source: Navidea Biopharmaceuticals